Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept

Figures & data

Table 1 Baseline Characteristics of Iraqi Patients with RA Who Initiated Etanercept Treatment

Patient Characteristics	All Patients, N=979	Earlier Tx (≤10 Years Since Onset of RA), n=579	Later Tx (>10 Years Since Onset of RA), n=400	p value (Earlier vs Later Tx)
Female, n (%)	813 (83)	469 (81)	344 (86)	0.046
Age, years	48.1 ± 12.1	45.2 ± 12.2	52.2 ± 10.6	<0.001
Duration of RA symptoms prior to etanercept Tx, years	10.1 ± 8.3	4.7 ± 2.4	18.0 ± 7.4	<0.001
CDAI	27.7 ± 11.6	27.0 ± 11.8	28.6 ± 11.4	0.044
DAS28	5.7 ± 1.2	5.6 ± 1.2	5.8 ± 1.2	0.031
Methotrexate Tx, n (%)	535 (55)	326 (56)	209 (52)	Not significant
Prednisolone Tx, n (%)	427 (44)	247 (43)	180 (45)	Not significant

Note: Data are mean ± standard deviation unless otherwise noted.

Abbreviations: CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score; RA, rheumatoid arthritis; Tx, treatment.

Figure 1 Change from baseline in (A) CDAI and (B) DAS28 in Iraqi patients stratified according to whether duration of RA symptoms prior to etanercept initiation was less than or greater than the population mean of 10 years.

Abbreviations: CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score.

Figure 2 Change from baseline in (A) CDAI and (B) DAS28 in Iraqi patients stratified according to the duration of RA prior to etanercept initiation.

Abbreviations: CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score.